Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-04-26 07:00:04
Oslo, 26 April 2022 - Targovax ASA announces that members of its executive
management team are invited for oral presentations and a panel discussion at the
5[th] Neoantigen Summit Europe in Amsterdam 27-28 April.
Presentation: Uncovering the Benefits of Personalized Vaccines in a Clinical
Setting
Presenter: Dr. Erik Digman Wiklund (CEO)
Date: 27 April 2022
Time: 10:00 CET
Presentation: Clinical Combination Strategies with Oncolytic Vaccines in Solid
Tumors
Presenter: Dr. Victor Levitsky (CSO)
Date: 28 April 2022
Time: 15:30 CET
Panel Discussion: Evaluating Combination Therapies to Maximize Anti-Tumour
Immune Activity
Participants from Targovax: Erik Digman Wiklund (CEO), Victor Levitsky (CSO)
Date: 28 April 2022
Time: 16:00 CET
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.
Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.
Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.